Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression

1. Horgan D Dodd S Berk M . A survey of combination antidepressant use in Australia. Australasian Psychiatry 2007; 15: 26–29.

2. Aguera LF Rojo JE de la Gandara J ii . Antidepressant combinations: Epidemiological considerations. Acta Psychiatrica Scandinavica 2005; 112(Suppl. 428)7–10.

3. Freedman SJ Fava M Kienke AS . Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current “next-step” practices. Journal of Clinical Psychiatry 2000; 61: 403–408.

4. McManus P Mant A Mitchell P . Co-prescription of SSRIs and TCAs in Australia: how often does it occur and who is doing it?. British Journal of Clinical Pharmacology 2001; 51: 93–98.

5. Ruhe HG Huyser J Swinkels JA . Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systemic review. Journal of Clinical Psychiatry 2006; 67: 1836–1855.

6. Bauer M Dopfmer S . Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. Journal of Clinical Psychopharmacology 1999; 19: 427–434.

7. Jackson IM . Does thyroid hormone have a role as adjunctive therapy in depression?. Thyroid 1996; 6: 63–67.

8. Dodd S Horgan D Malhi GS . To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders 2005; 89: 1–11.

9. Davidson J McLeod M Law-Yone B . A comparison of electrovconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Archives of General Psychiatry 1978; 35: 639–642.

10. Fava M Rosenbaum JF McGrath PJ . Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. American Journal of Psychiatry 1994; 151: 1372–1374.

11. Fava M Alpert J Nierenberg A . Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and non-responders to fluoxetine. Journal of Clinical Psychopharmacology 2002; 22: 379–387.

12. Nelson JC Mazure CM Jatlow PI . Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomised study. Biological Psychiatry 2004; 55: 296–300.

13. Licht RW Qvitzau S . Treatment strategies in patients with major depression not responding to first-line sertraline treatment. Psychopharmacology 2002; 161: 143–151.

14. Ferreri M Lavergne F Berlin I . Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatrica Scandinavica 2001; 103: 66–72.

15. Maes M Libbrecht I van Hunsel F . Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalised major depressed patients, including those with treatment resistance. Journal of Clinical Psychopharmacology 1999; 19: 177–182.

16. Carpenter LL , Yasmin S , Price LH . A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 2002; 51: 183–188.

17. Young JPR Lader MH Hughes WC . Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. British Medical Journal 1979; 2: 1315–1317.

18. Fava M Rush AJ Trivedi MH . Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study. Psychiatric Clinics of North America 2003; 26: 457–494.

19. Rush AJ Trivedi MH Wisniewski SR . Buproprion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 2006; 354: 1231–1242.

20. Trivedi MH Fava M Wisniewski SR . Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 2006; 354: 1243–1252.